N/A N=57 Stenting of the Superficial Femoral and/or Proximal Popliteal Artery Project
Atherosclerosis of Native Arteries of the Extremities
Primary: Primary Patency — 94.4 percentage of lesions
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=250 S.M.A.R.T.® Nitinol Self-Expandable Stent in the Treatment of Obstructive Superficial Femoral Artery Disease
Superficial Femoral Artery Disease
Primary: 12-month Primary Patency Rate — 143; 72 participants — p=0.437
N/A N=29 JetStream (JS) Atherectomy in Femoropopliteal In-Stent Restenotic Lesions
Restenosis · Peripheral Vascular Disease
Primary: Acute Procedural Success — 29 limbs
Phase 4 N=148 GORE VIABAHN ENDOPROSTHESIS Peripheral Vascular Disease Study
Peripheral Vascular Diseases
Primary: Efficacy: Primary Patency at Three Years — 24.2; 25.9 percentage of subjects
N/A N=146 Prevalence of Renal Artery Stenosis in Patients Referred for Cardiac Catheterization
Renal Artery Stenosis
Primary: Prevalence of Renal Artery Stenosis (RAS)
Phase 3 N=947 Benefits of Medical Therapy Plus Stenting for Renal Atherosclerotic Lesions
Atherosclerosis · Cardiovascular Diseases · Hypertension, Renovascular
Primary: Composite Endpoint: Death From Cardiovascular or Renal Causes, Stroke, Myocardial Infarction, Hospitalization for CHF, Progressive Renal Insufficiency, or Permanent…
N/A N=655 Aortoiliac Stenosis in Kidney Transplantation
Aorto-Iliac Arterial Stenosis · Peripheral Arterial Disease · Kidney Transplant Failure
Primary: Patient Survival — 322; 48; 6 Participants
N/A N=141 Iliac Artery Treatment With The Invatec Scuba™ Cobalt Chromium Stent (INTENSE)
Peripheral Artery Disease
Primary: Composite of Major Adverse Events (MAE) Defined as the Occurrence of In-hospital Myocardial Infarction (MI) or Target Segment Revascularization, Target Limb Loss, or…
N/A N=287 Safety and Effectiveness Study of EverFlex Stent to Treat Symptomatic Femoral-popliteal Atherosclerosis
Peripheral Vascular Diseases · Claudication
Primary: Primary Patency — 67.7 Percentage of participants with data
N/A N=76 CVT-SFA First in Human Trial for Treatment of Superficial Femoral Artery or Proximal Popliteal Artery
Femoral Artery Stenosis · Popliteal Artery Stenosis · Femoral Artery Occlusion
Primary: Number and Percentage of Participants With Freedom of Major Adverse Event (MAE) Rate — 72 Participants
N/A N=275 FLUENCY® PLUS Endovascular Stent Graft for In-stent Restenosis
Restenosis
Primary: Percentage of Participants With Access Circuit Primary Patency (ACPP) That is Superior for FLUENCY® PLUS Endovascular Stent Graft (Following Percutaneous Transluminal…
N/A N=171 Multi-center Study for Stent Graft System for Peripheral Artery
Peripheral Arterial Disease
Primary: Primary Assisted Patency — 91 Participants — p=<0.0001
N/A N=68 Renal Stent Placement for the Treatment of Renal Artery Stenosis in Patients With Resistant Hypertension
Renal Artery Stenosis · Hypertension, Renovascular
Primary: Primary Patency — 66 Subject-lesions — p=<.0001
N/A N=1,004 Femoral Arterial Access With Ultrasound Trial
Vascular Access Complications · Cardiac Catheterization · Peripheral Vascular Disease
Primary: Participants With Successful Common Femoral Artery Cannulation, as Determined by Femoral Angiography — 408; 431 participants
N/A N=196 The Complete® SE SFA Study for the Treatment of SFA/PPA Lesions
Peripheral Vascular Disease
Primary: Major Adverse Event (MAE) Rate — 11.0 percentage of participants
N/A N=474 Evaluation of the Zilver PTX Drug-Eluting Stent in the Above-the-Knee Femoropopliteal Artery
Peripheral Vascular Diseases
Primary: Event-free Survival Rate — 90.4; 83.9 Percentage of participants — p=<0.01
N/A N=121 Revolution™ Peripheral Atherectomy System for Lower Extremity Peripheral Arterial Revascularization
Peripheral Artery Disease
Primary: Safety Endpoint: Number of Participants With Freedom From Major Adverse Events — 110 Participants
N/A N=100 REFORM Clinical Study: Treatment of Renal Artery Stenosis With the Formula Balloon-Expandable Stent
Renal Artery Stenosis
Primary: Primary Patency of the Treated Renal Artery — 91 Lesions — p=<0.0001
N/A N=71 Evaluation of the 25 Centimeter (cm) GORE® VIABAHN® Endoprosthesis
Peripheral Vascular Diseases
Primary: Successful Completion of the Assigned Treatment — 76.7 percentage of subjects
N/A N=141 Absolute Pro® MOMENTUM™
Peripheral Artery Disease · Peripheral Vascular Disease
Primary: Major Adverse Event (MAE) — 0.0; 0.0; 0.0 percentage of participants
N/A N=200 ABRE Clinical Study of the Abre Venous Self-expanding Stent System
Iliofemoral Venous Obstruction
Primary: Primary Patency — 162 Participants — p=<0.0001
N/A N=162 Venous Stent for the Iliofemoral Vein Investigational Clinical Trial Using the DUO Venous Stent System
May-Thurner Syndrome · Deep Vein Thrombosis · Chronic Venous Insufficiency
Primary: Safety - Number of Participants Free From Major Adverse Events (MAEs) at 30 Days — 157 Participants
N/A N=264 Comparison of the SUpera® PERipheral System in the Superficial Femoral Artery
Peripheral Vascular Disease
Primary: Primary Safety Endpoint: Freedom From Death, Target Lesion Revascularization (TLR), or Any Amputation of the Index Limb to 30 (±7) Days. — 99.2; 99.6; 99.6; 100.0…
N/A N=276 A Multi-center Clinical Trial of the Misago™ Self-Expanding Stent System for Superficial Femoral Artery
Peripheral Vascular Disease
Primary: Primary Effectiveness Endpoint — 54.0 percentage of stent patency
N/A N=85 Comprehensive Magnetic Resonance of Peripheral Arterial Disease
Peripheral Artery Disease
Primary: Plaque Volume — 10.5; 10.5; 10.8 cm^3 — p=0.32
N/A N=112 Evaluation of the FreedomFlow™ Orbital Atherectomy System to Treat Peripheral Artery Disease
Peripheral Arterial Disease
Primary: Technical Success — 144 lesion
N/A N=134 A Study of the Gore VIABAHN BX for Treatment of Occlusive Disease in the Iliac Arteries.
Peripheral Arterial Disease
Primary: Composite of Major Adverse Events (MAEs) — 2.3 percentage of subjects experiencing MAE — p=<0.001
N/A N=32 PROMISE I Early Feasibility Trial of the LimFlow Stent Graft System
Critical Limb Ischemia · Chronic Limb-Threatening Ischemia
Primary: Amputation-free Survival — 90.6 Percentage of participants
N/A N=38 A Study on the Use of CorMatrix® ECM® for Femoral Arterial Reconstruction
Peripheral Vascular Disease
Primary: Device-Related Adverse Events — 0 Proportion of Participants that Experien
Phase 3 N=451 Stenting vs. Aggressive Medical Management for Preventing Recurrent Stroke in Intracranial Stenosis
Ischemic Stroke
Primary: Any Stroke or Death Within 30 Days of Enrollment or Any Revascularization Procedure OR an Ischemic Stroke in the Territory of the Symptomatic Intracranial Artery Beyond…